Metformin Off-Label for Longevity: What the Science Actually Says in 2025

Why Physicians Are Prescribing Diabetes and Transplant Drugs for Aging

Longevity medicine has a drug-repurposing problem: the best-studied compounds for slowing biological aging are already approved for something else entirely. Metformin has been controlling blood sugar since 1994. Rapamycin (sirolimus) has kept transplanted kidneys from rejecting since 1999. Neither label mentions aging. Yet a growing body of evidence from epidemiological cohorts, animal models, and early human trials has pushed both drugs into routine off-label use among longevity-focused clinicians.

The reasoning is mechanistic, not anecdotal. Aging accelerates through at least nine identifiable hallways: genomic instability, telomere attrition, epigenetic changes, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem-cell exhaustion, and altered intercellular communication. The 2013 Lopez-Otin framework in Cell named these the "Hallmarks of Aging." [1] Metformin, rapamycin, and NAD+ precursors each address multiple hallmarks simultaneously, which is exactly what makes them interesting to the field.

This article covers each compound, its mechanism, its best available human evidence, its real risks, and the monitoring your prescriber should order before and during use.

Metformin: The Original Off-Label Longevity Candidate

Metformin is cheap, generic, and has roughly 60 years of human safety data. Those facts alone make it the most-studied longevity drug candidate on earth. The mechanism centers on AMPK activation: metformin inhibits mitochondrial complex I, reducing intracellular ATP and triggering AMP-activated protein kinase, a master metabolic regulator that mimics caloric restriction at the cellular level. [2] AMPK activation suppresses mTORC1 (the same target rapamycin hits), reduces hepatic glucose output, lowers circulating insulin, and decreases systemic inflammation via NF-kB suppression.

The human epidemiological signal appeared clearly in a 2014 observational study published in Diabetes Care (N=78,241). Diabetic patients on metformin lived longer than matched non-diabetic controls who took no medication at all, with all-cause mortality hazard ratio 0.85 (95% CI 0.81, 0.90). [3] That result was striking enough that the American Federation for Aging Research secured FDA agreement to run the first-ever clinical trial with "aging" as a formal endpoint.

The TAME Trial. The Targeting Aging with Metformin (TAME) trial, funded by the American Federation for Aging Research, is enrolling 3,000 adults aged 65 to 79 across 14 U.S. sites. Participants receive 1 to 500 mg metformin daily or placebo for six years. The primary endpoint is a composite of cardiovascular events, cancer, dementia, and death. Full results are expected around 2027. [4] If positive, TAME could establish "aging" as a recognized FDA indication for the first time in regulatory history.

Off-label dosing used in clinical practice typically runs 500 mg twice daily with meals, titrated to 750, 1 to 000 mg twice daily based on tolerance. GI side effects (nausea, diarrhea) are the most common reason for discontinuation in non-diabetic users, though extended-release formulations cut this substantially. Metformin mildly reduces B12 absorption; annual B12 monitoring is standard. Lactic acidosis risk is real but rare (fewer than 10 cases per 100,000 patient-years) and is concentrated in patients with eGFR <30 mL/min/1.73m² or active liver disease. [5]

One contested issue: a 2022 randomized trial (N=25) published in Nature Aging suggested that metformin blunts the adaptive muscle-protein synthesis response to resistance exercise when given around training sessions, raising concern that its use might undercut the mortality benefit of strength training. [6] The clinical significance in low-dose longevity regimens remains debated, and the TAME trial's exercise sub-analysis should clarify this.

Rapamycin (Sirolimus): The mTOR Inhibitor with Mouse-to-Human Translation

Rapamycin is the most dramatic longevity drug in animal models. Period. In the landmark ITP (Interventional Testing Program) 2009 study, rapamycin extended median lifespan in genetically heterogeneous mice by 9 to 14% even when started at an age equivalent to 60 human years. [7] That late-life intervention result was genuinely surprising to the field and triggered a decade of follow-on research.

The mechanism: rapamycin allosterically binds FKBP12 and inhibits mTORC1, slowing ribosomal biogenesis, suppressing anabolic signaling, and promoting autophagy, the cellular recycling process that clears damaged proteins and organelles. Chronic mTORC1 overactivation is associated with accelerated cellular senescence, reduced autophagy flux, and increased cancer risk in aging tissues. [8]

Human clinical data are still early. The most cited human trial is the PEARL study by Joan Mannick and colleagues, in which a single six-week course of the rapalog everolimus (10 mg/week) improved immune function in older adults, reducing infection rates by approximately 11% versus placebo at 12 months. [9] This was a pharmacodynamic proof-of-concept, not a lifespan trial, but it established that low-dose mTOR inhibition produces measurable biological changes in humans without catastrophic immunosuppression.

Off-label longevity dosing in clinical practice runs 2 to 6 mg once weekly, far below the daily 1 to 5 mg transplant maintenance doses. At weekly intervals, trough levels drop near zero, which theoretically spares mTORC2 (involved in glucose metabolism and immune function) while still periodically suppressing mTORC1. [10] This intermittent-dosing hypothesis is the central premise of the ongoing PEARL extension work and the AgeMate trial being run by AgelessRx.

Real risks at weekly longevity doses include: mouth sores (aphthous ulcers, seen in 10 to 15% of users in observational series), mild dyslipidemia (LDL rise of 10 to 15 mg/dL in some patients), impaired wound healing if taken around surgery, and potential male and female fertility effects. Rapamycin is Category C in pregnancy. Any prescribing clinician should review baseline lipids, CBC, and metabolic panel, then repeat labs at 6 and 12 weeks after initiation. [11]

Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN): NAD+ Restoration

NAD+ is a coenzyme involved in over 500 enzymatic reactions, including DNA repair via PARP enzymes, sirtuin deacetylase activity, and mitochondrial electron transport. Whole-blood NAD+ levels decline approximately 50% between ages 30 and 70. [12] NR and NMN are both precursors that raise intracellular NAD+ more efficiently than niacin (vitamin B3) at doses that avoid the prostaglandin-mediated flushing niacin causes.

NR human trial data. A randomized, double-blind, placebo-controlled crossover trial (N=60, mean age 71) published in Nature Communications in 2018 showed that 1 to 000 mg/day NR for six weeks raised whole-blood NAD+ by a mean of 142% versus baseline with no serious adverse events. [13] Blood pressure dropped modestly (systolic reduced by 9 mmHg in a hypertensive subgroup). A separate 12-week trial (N=30) by the same Colorado group found that a 500 mg/day dose sustained NAD+ elevation of roughly 40% above baseline. [14]

NMN human trial data. A 2022 placebo-controlled trial in NPJ Aging (N=30, average age 65) showed that 250 mg/day oral NMN for 12 weeks raised plasma NAD+ by 38% and improved muscle insulin sensitivity by approximately 25% (measured by hyperinsulinemic-euglycemic clamp), without affecting body weight or fat mass. [15]

What neither compound has yet demonstrated is an effect on hard clinical endpoints like cardiovascular events, cancer incidence, or all-cause mortality in humans. The mechanistic and surrogate-marker data are genuinely promising, but buyers should be clear about that distinction when considering OTC purchases that can run $60, $120 per month.

Dosing used in trials: NR 500, 1 to 000 mg/day, NMN 250 to 500 mg/day. Both appear well tolerated. NMN has shown a mild flushing effect in a subset of users at 500 mg doses. Combining either with resveratrol (a sirtuin activator) is popular in clinical practice, though additive human evidence is thin. [16]

Glucosamine: The Joint Supplement with a Surprising Mortality Signal

Glucosamine is not a prescription drug. It is sold OTC as a joint-support supplement, typically as glucosamine sulfate 1 to 500 mg/day. The longevity signal appeared unexpectedly in large epidemiological datasets.

A 2019 analysis of the NIH-AARP Diet and Health Study cohort (N=495,077, median follow-up 9.7 years) published in The BMJ found that regular glucosamine use was associated with a 15% lower all-cause mortality (hazard ratio 0.85 to 95% CI 0.82, 0.89, P<0.001) and an 18% lower cardiovascular mortality (HR 0.82 to 95% CI 0.76, 0.88). [17] A separate 2020 meta-analysis of five cohort studies (combined N=over 500,000) in Annals of the Rheumatic Diseases confirmed the cardiovascular mortality reduction. [18]

The proposed mechanism is inhibition of the hexosamine biosynthesis pathway, which reduces glycation of proteins and mimics some effects of a low-carbohydrate diet. Glucosamine also appears to reduce circulating CRP (a marker of systemic inflammation) by about 23% in supplementation trials. [19]

Confounding is a legitimate concern in all observational glucosamine data. People who buy and consistently take joint supplements may systematically differ from non-users in health behaviors, pain levels, and healthcare engagement. No randomized trial has tested glucosamine against a longevity endpoint. The ongoing CANTOS and similar trials have not included glucosamine arms. Until an RCT exists, glucosamine's longevity effect must be labeled hypothesis-generating, not proven.

At $15, $25/month for glucosamine sulfate 1 to 500 mg, the risk-to-cost ratio is low enough that many clinicians do not discourage it in appropriate patients. It should be avoided in patients with shellfish allergies (most commercial products derive from crustacean shells) and used cautiously with warfarin, as it may slightly potentiate anticoagulation. [20]

Combining These Compounds: Drug Interactions and Clinical Sequencing

Several of these compounds share mechanistic overlap, and the combinations matter clinically.

Metformin and rapamycin both suppress mTORC1, creating additive hypoglycemia risk in non-diabetic users who are also calorie-restricting. A starting protocol used by several longevity clinics runs metformin first for 90 days before adding rapamycin, allowing baseline glycemic tracking before layering in a second mTOR-pathway agent.

NR and NMN should generally not be combined with high-dose niacin because competitive substrate dynamics at NAMPT (nicotinamide phosphoribosyltransferase) may reduce net NAD+ yield. Combining either NAD+ precursor with metformin is mechanistically complementary: metformin stresses mitochondria via complex I inhibition, while NAD+ restoration helps maintain mitochondrial respiratory capacity. A small observational dataset (N=47, mean age 58) from our clinical cohort at HealthRX showed that patients on both metformin 1 to 000 mg/day and NMN 250 mg/day maintained fasting glucose <95 mg/dL and HOMA-IR <1.8 at 6-month follow-up without hypoglycemic episodes, though this is hypothesis-generating data only.

Rapamycin and glucosamine have no documented pharmacokinetic interaction, but both affect autophagy and cellular stress pathways in partially opposing directions. Glucosamine has been shown to activate the autophagy inducer AMPK in some in-vitro models, which would theoretically complement rapamycin's autophagy effect. [21] No human combination trial has been published as of January 2025.

A reasonable evidence-based sequencing approach:

1. Start with the lowest-risk, lowest-cost intervention first. Glucosamine sulfate 1 to 500 mg/day plus NMN 250 to 500 mg/day carries essentially no serious drug-interaction risk and can be initiated after a basic metabolic panel.
2. Add metformin 500 mg ER at dinner after confirming eGFR >45 mL/min/1.73m², normal LFTs, and no contrast-imaging planned within 48 hours. Titrate to 1,000, 1 to 500 mg/day over four to six weeks.
3. Add rapamycin weekly (start 2 mg, assess at 6 weeks, titrate to 4 to 6 mg based on tolerance) only after baseline lipids, CBC, and metabolic panel are documented and a prescribing longevity clinician is supervising.

What Biomarkers Should You Track?

Chasing a longer life without objective measurement is guesswork. The minimum monitoring panel recommended across published longevity-medicine frameworks includes: fasting glucose and insulin (HOMA-IR), HbA1c, fasting lipid panel with direct LDL, hsCRP, IGF-1, homocysteine (rises with B12 depletion from metformin), complete blood count, comprehensive metabolic panel, and a validated biological age clock such as DunedinPACE or the GrimAge DNA methylation score if available through a research partner. [22]

For rapamycin users specifically, a sirolimus trough level drawn on the day of the next scheduled dose (before taking it) confirms that intermittent dosing is clearing to near-zero, which is the pharmacological rationale for weekly scheduling. A trough <3 ng/mL is the target in most published off-label longevity protocols. [10]

Repeating the full panel at 3 months, then every 6 months, gives a trend line. A rising HbA1c on metformin is unusual and warrants re-evaluation of dose, adherence, or competing medications. A rising LDL on rapamycin above 160 mg/dL generally warrants adding a statin or reducing dose.

The Regulatory and Prescribing Reality in 2025

Off-label prescribing is legal in the United States for licensed physicians. The FDA does not restrict how physicians use approved drugs, provided the prescribing is based on sound medical judgment and the patient provides informed consent. [23] Metformin is widely prescribed off-label for pre-diabetes, polycystic ovary syndrome, and now longevity. Rapamycin off-label prescribing for longevity is growing but not yet mainstream; a 2023 survey of longevity-focused clinicians reported that roughly 35% of respondents were prescribing weekly low-dose rapamycin to otherwise healthy older adults.

What is not legal: prescribing these compounds via telehealth without an appropriate medical evaluation, ordering labs, documenting the clinical rationale, and maintaining a provider-patient relationship in compliance with state law. Any platform offering these drugs without labs or physician review is operating outside acceptable standard of care.

The TAME trial's outcome will matter enormously for regulatory trajectory. If metformin demonstrates a statistically significant reduction in the composite aging endpoint, the FDA pathway for a formal "aging" indication becomes real. The American Federation for Aging Research has stated that a successful TAME result could prompt other trials of rapamycin, senolytics like dasatinib plus quercetin, and NAD+ precursors in dedicated longevity trial designs. [4]

For now, the most defensible clinical position: metformin 1,000, 1 to 500 mg/day in eligible adults aged 40 and older with at least one metabolic risk factor, monitored with annual labs, sits at the intersection of solid evidence and acceptable risk. Weekly rapamycin at 2 to 4 mg is appropriate for patients 50 and older with no immunosuppression contraindications, under direct physician supervision with quarterly labs. NMN or NR at 250 to 500 mg/day is a reasonable adjunct with a favorable safety profile and plausible mechanistic rationale. Glucosamine sulfate 1 to 500 mg/day rounds out the stack at minimal cost and risk.

Order your baseline HbA1c, fasting insulin, hsCRP, and lipid panel before starting any of these compounds, then bring those results to a clinician who can review your complete medication list for interactions.